Prescriptions for Therapies With Known CV Benefit Lacking After CV Events in T2D
Patients with type 2 diabetes who have had a cardiovascular event are not adequately prescribed glucose-lowering medications that might prevent subsequent CV events.
Dyslipidemia
CV Event Risk Increased With Rejected, Abandoned PCSK9i Prescriptions
Patients with rejected or abandoned prescriptions for PCSK9i have a significantly increased risk for cardiovascular events than those with paid prescriptions.
Angiopoietin-Like Protein 3 Inhibition Effectively Reduces Triglyceride Levels
Investigators sought to determine whether angiopoietin-like protein 3 inhibition might improve clinical outcomes in patients with hypertriglyceridemia.
Higher Intensity Therapy With Simvastatin-Ezetimibe May Benefit Elderly Patients After ACS
The updated AHA/ACC cholesterol management guidelines recommend moderate or high intensity statin therapy in patients over 75 years old with clinical atherosclerotic cardiovascular disease.
Subclinical CVD Linked to Higher Fall Risk in Older Adults
Subclinical cardiovascular disease (CVD) appears to be an independent risk factor for falls in older adults.
Extremely Low LDL Cholesterol Levels May Increase Stroke Risk
Cholesterol levels that are too low may increase the risk for hemorrhagic stroke.
Alirocumab May Have Greater CV Reduction Benefit in Patients With Diabetes
After an acute coronary syndrome event, alirocumab may offer greater risk reductions for future cardiovascular events in patients with diabetes vs those without diabetes, according to study results published in The Lancet Diabetes & Endocrinology. In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; ClinicalTrials.gov Identifier:…
RNAi Therapy for Homozygous Familial Hypercholesterolemia Receives Orphan Drug Designation
ARO-ANG3 reduces production of ANGPTL3, which has been shown to lower serum LDL as well as serum and liver triglyceride.
FDA Approves Sprinkle Formulation of Rosuvastatin
Ezallor Sprinkle is intended for patients who have difficulty swallowing.
“Cardiabetes”: Is It Time for a New Subspecialty?
With a growing number of patients with both diabetes and cardiovascular disease, clinicians consider the need for a new specialty: cardiometabolic medicine.
Next post in Diabetes
